Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can tea compounds sharpen focus in ADHD and autism? new study seeks answers

NCT ID NCT07189442

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 25, 2026 · Updated 2 times

Summary

This pilot study tests whether a combination of two natural compounds, L-theanine and paraxanthine, can temporarily improve attention and self-control in adults with ADHD or autism. About 24 participants will complete thinking tests and brain scans after taking the supplement or a placebo. The goal is to see if this combo offers a safe, short-term cognitive boost.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

17 people

The number who actually took part.

Started

Oct 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults (18+ years) diagnosed by a physician (per self-report) with ADHD or ASD \* Participants with a dual diagnosis and ASD and ADHD will be recruited but will only be included in the ASD group - their concurrent ADHD diagnosis will be included as an additional variable in exploratory analyses Exclusion Criteria: 1. Subjects with gross visual or auditory impairments that might limit their ability to perform neuropsychological tasks 2. Inability to read and follow written instructions 3. Physical, neurological, intellectual, or psychiatric impairments (except ADHD or ASD) that could affect cognitive and motor functions 4. Subjects on medications including antidepressants and antipsychotics that may affect performance in the tasks 5. Subjects on medications that are likely to interact with the administered substances, including regular intake of medication that could alter visual, auditory, cognitive, or motor functions (except stimulants) 6. History of head injury resulting in loss of consciousness/history of brain surgery 7. Subjects who have developed adverse effects when caffeine/paraxanthine /L-theanine/corn starch (will be in placebo) containing products were consumed 8. Subjects who are unwilling or unable to refrain from intake of L-theanine/ caffeine/ paraxanthine containing food or beverages within the 24 hours prior to each study visit 9. Intake of drugs containing caffeine, other phosphodiesterase inhibitors, or adenosine receptor blockers within the past 3 months 10. Intake of medications known to have pharmacological interactions with paraxanthine within the past 3 months 11. Current/past diagnosis of tics or other forms of dyskinesia 12. History of headache, drowsiness, anxiety, insomnia, or nausea following intake of caffeine or caffeine-containing beverages 13. Current/past history of smoking and/or alcohol or drug abuse 14. Subjects with absolute contraindications to undergo MRI after being screened by the TTNI safety screening sheet (Appendix) 15. Unwillingness or inability to entirely refrain from the use of electronic devices during study visits 16. Unwillingness or inability to follow written, on-screen, and verbal instructions given by the study team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Attention-deficit/hyperactivity disorder (ADHD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Texas Tech University

    Lubbock, Texas, 79430, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.